RESUMO
INTRODUCTION AND OBJECTIVES: Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary vascular resistance, right ventricular dysfunction and death. Despite scientific advances, is still associated with high morbidity and mortality. The aim is to describe the clinical approach and determine the prognostic factors of patients with PAH treated in a national reference center over 30 years. METHODS: Three hundred and seventy nine consecutive patients with PAH (January 1984 to December 2014) were studied. Were divided into 3 periods of time: before 2004, 2004-2009 and 2010-2014. Prognostic factors (multivariate analysis) were analyzed for clinical deterioration. RESULTS: Median age was 44 years (68.6% women), functional class III-IV: 72%. An increase was observed in more complex etiologies in the last period of time: Pulmonary venooclusive disease and portopulmonary hypertension. Upfront combination therapy significantly increased (5% before 2004 vs 27% after 2010; P < .05). Multivariate analysis showed prognostic significance in age, sex, etiology and combined clinical variables as they are independent predictors of clinical deterioration (P < .05). Survival free from death or transplantation for the 1st, 3rd and 5th year was 92.2%, 80.6% and 68.5% respectively. The median survival was 9 years (95% confidence interval, 7.532-11.959) CONCLUSIONS: The PAH is a heterogeneous and complex disease, the median survival free from death or transplantation in our series is 9 years after diagnosis. The structure of a multidisciplinary unit PAH must adapt quickly to changes that occur over time incorporating new diagnostic and therapeutic techniques.
Assuntos
Hipertensão Pulmonar/mortalidade , Adulto , Idade de Início , Anti-Hipertensivos/uso terapêutico , Progressão da Doença , Intervalo Livre de Doença , Feminino , Humanos , Hipertensão Pulmonar/terapia , Estimativa de Kaplan-Meier , Transplante de Pulmão/estatística & dados numéricos , Transplante de Pulmão/tendências , Masculino , Pessoa de Meia-Idade , Prognóstico , Espanha/epidemiologiaRESUMO
BACKGROUND: Cardiac allograft vasculopathy (CAV) is a major cause of long-term morbidity and mortality after heart transplantation (HTx), whose relationship with CMV infection is uncertain. This study evaluated the influence of CMV infection in the development of CAV. METHODS: We enrolled 166 consecutive HTx recipients who underwent their first transplant from January 1995 to July 2002. All patients received 14 days of intravenous ganciclovir and were prospectively monitored for CMV infection during the first year after HTx. CAV was diagnosed by coronary angiography performed at 1, 5, and 10 years after HTx, following the new criteria of the International Society for Heart and Lung Transplantation. We collected all variables potentially related with the development of CAV. Risk factors were studied using a complementary log-log model. RESULTS: After a median follow-up of 11 years (range, 1-17 years), 72 patients (43%) developed CAV (63.8% CAV(1), 15.2% CAV(2), 20.8% CAV(3)). Symptoms secondary to CAV were present in 32% of these patients, and 8% died because of it. In the regression multivariate analysis, independent variables associated with the development of CAV were donor age (hazard ratio [HR], 1.028; 95% confidence interval [CI], 1.002-1.053; p < 0.028), presence of cellular acute rejection ≥ 2R (HR, 1.764; 95% CI, 1.011-3.078; p < 0.0414), CMV infection (HR, 2.334; 95% CI, 1.043-5.225; p < 0.0354), and not having been treated with a calcium channel blocker (HR, 0.472; 95% CI, 0.275-0.811; p < 0.0055). CONCLUSIONS: Standardized angiographic criteria show CMV infection is associated with the development of CAV.
Assuntos
Infecções por Citomegalovirus/etiologia , Rejeição de Enxerto/virologia , Insuficiência Cardíaca/cirurgia , Insuficiência Cardíaca/virologia , Transplante de Coração/efeitos adversos , Adulto , Idoso , Infecções por Citomegalovirus/diagnóstico , Infecções por Citomegalovirus/mortalidade , Intervalo Livre de Doença , Feminino , Rejeição de Enxerto/epidemiologia , Insuficiência Cardíaca/mortalidade , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de RiscoRESUMO
INTRODUCTION: Pulmonary thromboendarterectomy is the treatment of choice in chronic thromboembolic pulmonary hypertension. We report our experience with this technique. METHODS: Between February 1996 and June 2014, we performed 106 pulmonary thromboendarterectomies. Patient population, morbidity and mortality and the long-term results of this technique (survival, functional improvement and resolution of pulmonary hypertension) are described. RESULTS: Subjects' mean age was 53±14 years. A total of 89% were WHO functional class III-IV, presurgery mean pulmonary pressure was 49±13mmHg and mean pulmonary vascular resistance was 831±364 dynes.s.cm(-5). In-hospital mortality was 6.6%. The most important post-operative morbidity was reperfusion pulmonary injury, in 20% of patients; this was an independent risk factor (p=0.015) for hospital mortality. With a 31-month median follow-up (interquartile range: 50), 3- and 5-year survival was 90 and 84%. At 1 year, 91% were WHO functional class I-II; mean pulmonary pressure (27±11mmHg) and pulmonary vascular resistance (275±218 dynes.s.cm(-5)) were significantly lower (p<0.05) than before the intervention. Although residual pulmonary hypertension was detected in 14 patients, their survival at 3 and 5 years was 91 and 73%, respectively. CONCLUSIONS: Pulmonary thromboendarterectomy offers excellent results in chronic thromboembolic pulmonary hypertension. Long-term survival is good, functional capacity improves, and pulmonary hypertension is resolved in most patients.
Assuntos
Endarterectomia/métodos , Hipertensão Pulmonar/etiologia , Embolia Pulmonar/cirurgia , Trombectomia/métodos , Adulto , Idoso , Ponte Cardiopulmonar , Doença Crônica , Endarterectomia/estatística & dados numéricos , Feminino , Seguimentos , Mortalidade Hospitalar , Humanos , Hipotermia Induzida , Hipóxia/etiologia , Hipóxia/terapia , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/mortalidade , Complicações Pós-Operatórias/terapia , Embolia Pulmonar/complicações , Recuperação de Função Fisiológica , Traumatismo por Reperfusão/etiologia , Traumatismo por Reperfusão/terapia , Respiração Artificial , Trombectomia/estatística & dados numéricos , Resultado do Tratamento , Resistência Vascular , Adulto JovemRESUMO
INTRODUCTION: An excessive risk for bacteremia has recently been reported in patients with pulmonary arterial hypertension (PAH) treated with intravenous treprostinil. We aimed to assess this association in a cohort of patients from a Spanish referral center. PATIENTS AND METHODS: We performed a retrospective cohort study that included 55 patients diagnosed with PAH who received a continuous intravenous infusion of a prostanoid (epoprostenol or treprostinil) for ≥1month at our center between January 1991 and December 2011. The risk factors associated with the incidence of bacteremia were analyzed with the log-rank test. RESULTS: After a total follow-up of 64,453 treatment days, we found 12 episodes of bacteremia: Staphylococcus aureus (5 episodes), non-fermenting gram-negative bacilli (4 episodes), other gram-positive cocci (2 episodes), and Enterobacter cloacae (one episode). The incidence of bacteremia was 0.118 episodes per 1,000 treatment days in patients receiving epoprostenol versus 0.938 episodes per 1,000 treatment-days in patients receiving treprostinil (P=.0037). All episodes of bacteremia due to Gram-negative bacilli were diagnosed in patients on treprostinil. In the univariate analysis the treatment with intravenous treprostinil was associated with the incidence of bacteremia (hazard ratio: 4.09; 95% confidence interval: 1.24-14.53), although the low number of events prevented us from performing a multivariate analysis. CONCLUSIONS: Therapy with intravenous treprostinil is associated with a higher risk for bacteremia, especially due to non-fermenting Gram-negative bacilli. This association should be taken in consideration when choosing empirical antibiotic therapy for patients with PAH and sepsis.
Assuntos
Anti-Hipertensivos/efeitos adversos , Bacteriemia/induzido quimicamente , Bacteriemia/epidemiologia , Epoprostenol/análogos & derivados , Hipertensão Pulmonar/tratamento farmacológico , Adulto , Anti-Hipertensivos/administração & dosagem , Estudos de Coortes , Epoprostenol/administração & dosagem , Epoprostenol/efeitos adversos , Hipertensão Pulmonar Primária Familiar , Feminino , Bactérias Gram-Negativas , Humanos , Incidência , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Estudos RetrospectivosRESUMO
La valoración de la capacidad funcional en los pacientes con hipertensión arterial pulmonar forma parte del protocolo diagnóstico inicial y del seguimiento. El grado de intolerancia al ejercicio tiene importantes implicaciones pronósticas y en la elección de tratamiento. Clásicamente, esta valoración se ha realizado mediante la prueba de caminata de 6 minutos. La prueba de esfuerzo cardiopulmonar, ampliamente utilizada en la disfunción ventricular izquierda, se está introduciendo como nueva herramienta en la valoración funcional de los pacientes con hipertensión arterial pulmonar, sobre todo en la de aquellos con menos limitaciones funcionales. Aparte de realizar una valoración no invasiva y objetiva de la capacidad de ejercicio, describe cuáles son los mecanismos fisiopatológicos subyacentes a dicha limitación. Es capaz también de identificar a los pacientes con cortocircuito derecha-izquierda secundario a foramen oval permeable. Tiene implicaciones pronósticas y puede emplearse para analizar la respuesta al tratamiento. Sin embargo, es compleja y requiere una gran experiencia para realizarla e interpretar sus resultados. A continuación, revisaremos el comportamiento de los pacientes con hipertensión arterial pulmonar en la prueba de esfuerzo cardiopulmonar describiendo brevemente la respuesta de nuestros pacientes y comparando los resultados con la prueba de caminata de 6 minutos.
The assessment of functional capacity is part of the diagnosisand management of patients with pulmonaryarterial hypertension. Exercise capacity impairment determines prognosis and establishes which is the besttreatment option. Practicing clinicians use various exercisemodalities in pulmonary arterial hypertension: the 6-minute walk test is the one most frequently used. Cardiopulmonary exercise testing, widely used in leftventricle dysfunction, is starting to be incorporated as anew noninvasive tool for functional assessment inpulmonary hypertensive patients, especially in those withless severe disease. Apart from providing objective information about exercise limitation it can describe the pathophysiological bases of functional impairment and it identifies patients with exercise induced right-to-leftshunt due to patent foramen ovale. Cardiopulmonary exercise testing parameters predict prognosis and assessthe response to drugs. However, it is complex and requiresgreat level of experience for interpreting its results. Thisarticle describes pulmonary hypertensive patient responseto cardiopulmonary exercise testing. Finally, we will brieflyanalyze our results comparing them with 6-minute walktest.